Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer
Status:
Recruiting
Trial end date:
2022-04-28
Target enrollment:
Participant gender:
Summary
Many prostate cancer are slow or non progressive forms that would never impair quality or
quantity of like of life if undetected. For this localized prostate cancer, the
recommendation is an active surveillance, however often experienced by the patient as a lack
of care. Thus the introduction of new potent androgen receptor inhibitor raise the question
of the benefit of early hormonal therapy in localized prostate cancers.
The aim of this study is to assess whether treatment with an oral androgen receptor inhibitor
could influence the progression of localized prostate cancer and delay the time to local
treatment initiation.